SCHEMBL4138368

SCHEMBL4138368

COc1cc(-n2cccc2)c(Cl)cc1C=C1SC(Nc2ccc(CC(=O)NS(=O)(=O)c3ccc(C)cc3)cc2)=NC1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.42
ERBB2 P04626 9/20 0.41
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36
PRMT5 O14744 1/20 0.35
KMT2A Q03164 6/20 0.35
POLB P06746 5/20 0.35
MAPT P10636 2/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
RECQL P46063 1/20 0.35
MEN1 O00255 5/20 0.34
NSD2 O96028 1/20 0.34
GFER P55789 1/20 0.34
USP2 O75604 1/20 0.34
PTGES O14684 1/20 0.34
ALOX5 P09917 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4138363 1.00 EGFR (0.42) EGFRERBB2ADRB2ADRB1ADRB3
SCHEMBL4635258 0.86 EGFR (0.48) EGFRERBB2ADRB2ADRB1ADRB3
SCHEMBL4137378 0.85 ALOX5 (0.37) EGFRKMT2APOLBMAPTLMNA
SCHEMBL4137375 0.85 ALOX5 (0.37) EGFRKMT2APOLBMAPTLMNA
SCHEMBL4635253 0.85 EGFR (0.48) EGFRERBB2ADRB2ADRB1ADRB3
SCHEMBL4635255 0.85 EGFR (0.48) EGFRERBB2ADRB2ADRB1ADRB3
SCHEMBL4127446 0.83 EGFR (0.41) EGFRERBB2ADRB2ADRB1ADRB3
SCHEMBL4122888 0.83 EGFR (0.50) EGFRERBB2PRMT5KMT2APOLB
SCHEMBL4122891 0.83 EGFR (0.50) EGFRERBB2PRMT5KMT2APOLB
SCHEMBL4122898 0.80 MAPT (0.49) EGFRERBB2KMT2APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ EGFR 729/4885ERBB2 138/4885ADRB2 2517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.